WallStreetZen

NYSE: MCK
Mckesson Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MCK

Based on 5 analysts offering 12 month price targets for Mckesson Corp.
Min Forecast
$226.00+0.89%
Avg Forecast
$237.00+5.8%
Max Forecast
$270.00+20.54%

Should I buy or sell MCK stock?

Based on 5 analysts offering ratings for Mckesson Corp.
Buy
Strong Buy
3 analysts 60%
Buy
0 analysts 0%
Hold
2 analysts 40%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

MCK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Anonymous
Morgan Stanley
Strong BuyMaintains$250.00+11.61%2021-12-06
Credit Suisse
Bottom 3%
3
HoldMaintains$230.00+2.68%2021-11-08
Mizuho
Top 13%
88
HoldMaintains$229.00+2.23%2021-11-03
Barclays
Top 30%
71
Strong BuyMaintains$270.00+20.54%2021-11-02Find out why
Argus Research
Top 30%
71
Strong BuyUpgrades$230.00+2.68%2021-03-30
Morgan Stanley
Top 5%
96
Strong BuyMaintains$226.00+0.89%2021-02-03

1 of 1

Forecast return on equity

Is MCK forecast to generate an efficient return?
Company
-672.5%
Industry
36.34%
Market
37.06%
MCK's Return on Equity is forecast to be low in 3 years (-672.5%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is MCK forecast to generate an efficient return on assets?
Company
6.04%
Industry
13.58%
MCK is forecast to generate lower Return on Assets (6.04%) than the US Healthcare industry average (13.58%)
Forecast

MCK earnings per share forecast

What is MCK's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$20.27-167.21%
Avg 2 year Forecast
$21.09-169.93%
Avg 3 year Forecast
$25.15-183.39%

MCK revenue forecast

What is MCK's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$259.0B+3.18%
Avg 2 year Forecast
$264.3B+5.29%
Avg 3 year Forecast
$262.6B+4.61%
MCK's revenue is forecast to grow at a rate of 1.9% per year, which is not exceptional
Forecast

MCK revenue growth forecast

How is MCK forecast to perform vs Healthcare companies and vs the US market?
Company
1.9%
Industry
11.63%
Market
10.03%
MCK's revenues are forecast to grow slower (1.9% per year) than the US Healthcare industry average (11.63%)
Forecast
MCK's revenues are forecast to grow slower (1.9% per year) than the US market average (10.03%)
Forecast

Mckesson Corp Stock Forecast FAQ

Is Mckesson Corp Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: MCK) stock is to Buy MCK stock.

Out of 5 analysts, 3 (60%) are recommending MCK as a Strong Buy, 0 (0%) are recommending MCK as a Buy, 2 (40%) are recommending MCK as a Hold, 0 (0%) are recommending MCK as a Sell, and 0 (0%) are recommending MCK as a Strong Sell.

What is MCK's earnings growth forecast for 2022-2024?

(NYSE: MCK) Mckesson Corp's forecast annual earnings growth rate of N/A is not forecast to beat the US Healthcare industry's average forecast earnings growth rate of 17.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.37%.

Mckesson Corp's earnings in 2021 is -$4,807,000,000.On average, 6 Wall Street analysts forecast MCK's earnings for 2022 to be $3,094,867,505, with the lowest MCK earnings forecast at $3,064,331,072, and the highest MCK earnings forecast at $3,126,930,760. On average, 5 Wall Street analysts forecast MCK's earnings for 2023 to be $3,220,066,881, with the lowest MCK earnings forecast at $3,168,154,945, and the highest MCK earnings forecast at $3,278,086,104.

In 2024, MCK is forecast to generate $3,839,956,475 in earnings, with the lowest earnings forecast at $3,839,956,475 and the highest earnings forecast at $3,839,956,475.

What is MCK's revenue growth forecast for 2022-2024?

(NYSE: MCK) Mckesson Corp's forecast annual revenue growth rate of 1.9% is not forecast to beat the US Healthcare industry's average forecast revenue growth rate of 11.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.03%.

Mckesson Corp's revenue in 2021 is $250,991,000,000.On average, 3 Wall Street analysts forecast MCK's revenue for 2022 to be $39,538,929,456,807, with the lowest MCK revenue forecast at $39,336,802,698,169, and the highest MCK revenue forecast at $39,679,041,300,080. On average, 4 Wall Street analysts forecast MCK's revenue for 2023 to be $40,347,282,587,733, with the lowest MCK revenue forecast at $39,371,249,321,641, and the highest MCK revenue forecast at $41,499,547,106,381.

In 2024, MCK is forecast to generate $40,089,206,670,822 in revenue, with the lowest revenue forecast at $40,089,206,670,822 and the highest revenue forecast at $40,089,206,670,822.

What is MCK's forecast return on assets (ROA) for 2022-2024?

(NYSE: MCK) forecast ROA is 6.04%, which is lower than the forecast US Healthcare industry average of 13.58%.

What is MCK's Price Target?

According to 5 Wall Street analysts that have issued a 1 year MCK price target, the average MCK price target is $237.00, with the highest MCK stock price forecast at $270.00 and the lowest MCK stock price forecast at $226.00.

On average, Wall Street analysts predict that Mckesson Corp's share price could stay at $237.00 by Nov 8, 2022. The average Mckesson Corp stock price prediction forecasts a potential downside of N/A from the current MCK share price of $224.00.

What is MCK's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: MCK) Mckesson Corp's current Earnings Per Share (EPS) is -$30.16. On average, analysts forecast that MCK's EPS will be $20.27 for 2022, with the lowest EPS forecast at $20.07, and the highest EPS forecast at $20.48. On average, analysts forecast that MCK's EPS will be $21.09 for 2023, with the lowest EPS forecast at $20.75, and the highest EPS forecast at $21.47. In 2024, MCK's EPS is forecast to hit $25.15 (min: $25.15, max: $25.15).

What is MCK's forecast return on equity (ROE) for 2022-2024?

(NYSE: MCK) forecast ROE is -672.5%, which is considered weak.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.